Abstract
Orphan drugs for patients with ultra-rare diseases: between cost-effectiveness and equality of access to cure http://ow.ly/Zlmf4
MeSH terms
-
Drug Discovery / legislation & jurisprudence
-
Europe / epidemiology
-
Government Regulation
-
Health Policy / legislation & jurisprudence*
-
Health Services Accessibility / legislation & jurisprudence*
-
Humans
-
Lung Diseases / classification
-
Lung Diseases / diagnosis
-
Lung Diseases / drug therapy*
-
Lung Diseases / epidemiology
-
Orphan Drug Production / legislation & jurisprudence*
-
Rare Diseases / classification
-
Rare Diseases / diagnosis
-
Rare Diseases / drug therapy*
-
Rare Diseases / epidemiology